Common Patient Concerns about the Use of Glucagon-Like Peptide-1 Receptor Agonists in Diabetes Mellitus Management

Authors

Jeffrey S. Freeman, Philadelphia College of Osteopathic MedicineFollow
James R. Gavin
Craig W. Spellman

Document Type

Article

Publication Date

1-1-2012

Abstract

The authors present a case of a 46-year-old woman with type 2 diabetes mellitus who has been on a treatment regimen involving diet, exercise, and metformin. After 2 years of treatment, she has a body mass index of 35 and a glycosylated hemoglobin level of 8.0%, and this level is increasing. Her physician recommends adding a glucagon-like peptide-1 (GLP-1) receptor agonist to her treatment regimen, prompting her to ask several questions. The authors present these questions along with proposed answers, highlighting the practical application of GLP-1 receptor agonists in the context of common patient concerns.

Publication Title

Journal of the American Osteopathic Association

Volume

112

Issue

1 Supplement 1

First Page

S22

Last Page

S24

PubMed ID

22267301

Comments

This article was published in Journal of the American Osteopathic Association, Volume 112, Issue 1, Supplement 1, January 2012, Pages S22-S24.

The published version is available at http://www.jaoa.org/content/112/1_suppl_1/S22.long

Copyright © 2012 by the American Osteopathic Association

Recommended Citation

Freeman, Jeffrey S.; Gavin, James R.; and Spellman, Craig W., "Common Patient Concerns about the Use of Glucagon-Like Peptide-1 Receptor Agonists in Diabetes Mellitus Management" (2012). PCOM Scholarly Works. 204.
https://digitalcommons.pcom.edu/scholarly_papers/204